Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

AGM Statement

22 Oct 2012 07:00

RNS Number : 1601P
ABCAM Plc
22 October 2012
 



For immediate release 22 October 2012

 

 

ABCAM PLC

("Abcam" or "the Company")

 

AGM Statement

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, is this morning holding its Annual General Meeting.

Michael Redmond, Abcam's Chairman, will make the following statement:

"Last month, in our preliminary results, we highlighted the challenges faced in our Western markets as Governments address fiscal deficits, including the effect of uncertainty about future levels of research funding on researchers' spending. These challenges remain a feature of our markets, particularly in the US ahead of the election later this year.

"Despite this backdrop, the Board believes that Abcam is well positioned to deliver continued growth. The integration of the Epitomics reagents business is proceeding successfully and the Board is pleased with the Company's profitability in the first three months of the financial year."

 

For further information please contact:

 

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

Numis Securities - Nominated Advisor and Joint Broker

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Advisor

James Black - Corporate Broking

Peel Hunt LLP - Joint Broker

+ 44 (0) 207 418 8900

Andy Crossley - Corporate Broking

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 600 staff across its eight operating companies.

Abcam now has an online catalogue of over 98,000 products sourced from more than 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website, www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMBKDDNKBDBOKB
Date   Source Headline
9th Dec 20162:56 pmRNSDirector/PDMR Shareholding
8th Dec 20165:09 pmRNSDirector/PDMR Shareholding
5th Dec 20162:45 pmRNSDirector/PDMR Shareholding
1st Dec 20164:01 pmRNSTotal Voting Rights
10th Nov 20162:00 pmRNSApplication for admission to trading
10th Nov 20167:00 amRNSAxioMx technology milestones accelerated
7th Nov 201611:21 amRNSDirector/PDMR Shareholding
7th Nov 20169:30 amRNSDirector/PDMR Shareholding
2nd Nov 20164:22 pmRNSResult of AGM
2nd Nov 20167:00 amRNSAGM Statement
1st Nov 20163:02 pmRNSTotal Voting Rights
27th Oct 20167:00 amRNSDirector/PDMR Shareholding
24th Oct 20167:00 amRNSNew facility at Cambridge Biomedical Campus
3rd Oct 20161:07 pmRNSTotal Voting Rights
3rd Oct 20167:00 amRNSDirector/PDMR Shareholding
28th Sep 20168:43 amRNSDirector/PDMR Shareholding
26th Sep 20167:19 amRNSAnnual Financial Report
21st Sep 20167:00 amRNSHolding(s) in Company
21st Sep 20167:00 amRNSDirector/PDMR Shareholding
15th Sep 20162:25 pmRNSDirector/PDMR Shareholding
12th Sep 20167:00 amRNSPreliminary Results
2nd Sep 20167:00 amRNSApplication for admission to trading
24th Aug 20167:00 amRNSNotice of Results
23rd Aug 20163:01 pmRNSBlock listing Interim Review
3rd Aug 20167:00 amRNSDirectorate Change
1st Aug 20161:11 pmRNSTotal Voting Rights
25th Jul 20167:00 amRNSPre-Close Period Update
1st Jul 20162:12 pmRNSTotal Voting Rights
20th Jun 20167:00 amRNSAbcam to appoint Gavin Wood as CFO
1st Jun 20164:38 pmRNSTotal Voting Rights
3rd May 20162:03 pmRNSTotal Voting Rights
19th Apr 20162:35 pmRNSDirector/PDMR Shareholding
1st Apr 20161:50 pmRNSTotal Voting Rights
24th Mar 20162:29 pmRNSDirector/PDMR Shareholding
24th Mar 20167:00 amRNSPosting of Half Yearly Report
22nd Mar 20169:33 amRNSDirector/PDMR Shareholding
7th Mar 20167:00 amRNSDirectorate Change
7th Mar 20167:00 amRNSHalf Yearly Report
10th Feb 201610:59 amRNSNotice of Results
8th Feb 20163:58 pmRNSBlocklisting Interim Review
1st Feb 20162:06 pmRNSTotal Voting Rights
29th Jan 20163:09 pmRNSHolding(s) in Company
25th Jan 20167:00 amRNSHalf Year Trading Update
4th Jan 20163:02 pmRNSTotal Voting Rights
7th Dec 20153:57 pmRNSDirector/PDMR Shareholding
7th Dec 20151:59 pmRNSDirector/PDMR Shareholding
1st Dec 20154:30 pmRNSTotal Voting Rights
12th Nov 20153:22 pmRNSApplication for admission to trading - update
12th Nov 20152:56 pmRNSDirector/PDMR Shareholding
11th Nov 20154:26 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.